PegBio Co., Ltd.

15 clinical trials · Sponsor

Record	Firm	Date
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects (NCT06350812)	PegBio Co., Ltd.	2024-05-27
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects. (NCT06147544)	PegBio Co., Ltd.	2023-07-06
Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy (NCT05326490)	PegBio Co., Ltd.	2022-05-30
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function (NCT05328843)	PegBio Co., Ltd.	2022-05-01
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study (NCT05021666)	PegBio Co., Ltd.	2020-07-29
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy (NCT04504396)	PegBio Co., Ltd.	2020-06-23
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects (NCT04504370)	PegBio Co., Ltd.	2020-04-27
Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus (NCT03973515)	PegBio Co., Ltd.	2019-08-27
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes (NCT03604419)	PegBio Co., Ltd.	2018-06-13
Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects (NCT03520972)	PegBio Co., Ltd.	2018-06-05

Track PegBio Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.